Pfizer (NYSE: PFE ) releases its Q1 earnings very soon, and buying the stock pre-earnings looks like a great opportunity to lock in a compelling 7.55% dividend yield. The dividend is highly likely safe because Pfizer's revenue trajectory is stabilizing after theWith a decade at a Big 4 audit firm specializing in the banking, mining, and energy sectors, I bring a strong foundation in finance and strategy. Currently, I serve as the Head of Finance for a leading owner and operator of retail real estate, where ...

Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Pfizer (PFE) and Eli Lilly (LLY) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets companies with positive earnings est ...

The upcoming report from Pfizer (PFE) is expected to reveal quarterly earnings of $0.64 per share, indicating a decline of 22% compared to the year-ago period. Analysts forecast revenues of $13.88 billion, representing a decrease of 6.7% year over year.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Before a company announc ...

Having significant capital in the bank when investing in equities is helpful, but is by no means necessary. Even with a relatively modest sum, like $30, it's possible to acquire one whole share of a top corporation that's likely to perform well in the long run. If you're patient and hold on to it through the kind of market volatility we're experiencing, while occasionally purchasing more shares, that should result in excellent returns.Which stocks trading for less than $30 per share are worth investing in t ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.Pfizer Inc. (NYSE: PFE ), the New York-based Pharma giant whose COVID vaccine Comirnaty earned the company >$85bn between 2021–2023, and whose COVID antiviral Paxlovid earn ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Pfizer (PFE) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on April 29. On the othe ...

With a staggering 7.63% dividend yield, Pfizer (NYSE: PFE ) is a mouth-watering candidate for income-seeking investors. But is this high yield stock a trap that is too good to be true, or is it a genuine opportunity?I am a conservative yet opportunistic value investor who has been investing since 2005. I am fact-driven, preferring to let financial data inform me of a company's health, followed by qualitative analysis to fill in the gaps to paint a holistic picture of a company's growth prospects.My work is ...

文章核心观点 - 减肥疗法市场近年来火热，但辉瑞在该市场前景不佳，不过公司在其他市场前景好、财务表现强，股票仍值得买入 [1][2][10] 减肥疗法市场情况 - 减肥疗法市场虽不是制药行业最大治疗领域，但近年来火热，Wegovy和Zepbound等药物销售增长迅速 [1] 辉瑞在减肥市场的挫折 - 辉瑞在推出能与Wegovy和Zepbound竞争的药物方面遇诸多挫折，候选药物lotiglipron因潜在肝脏问题在1期研究后停用 [3] - 领先项目danuglipron也有问题，每日两次版本在2期临床试验中虽疗效好但副作用率高，公司放弃该配方 [4] - 4月中旬辉瑞决定放弃danuglipron项目，每日一次版本在2期研究中致患者肝损伤，此前也有肝脏问题相关情况 [5] 投资者应对及辉瑞其他优势 - 药物临床试验失败常见，辉瑞不会放弃减肥市场，且市场未将danuglipron成功计入股价，此次失败不影响大局 [6] - 辉瑞在肿瘤学市场历史表现强，一年多前以430亿美元收购癌症专家Seagen，有望在肿瘤学领域取得临床和监管胜利 [7][8] - 辉瑞财务表现强劲，去年营收同比增长7%至636亿美元，调整后每股收益同比飙升69%至3.11美元 [9] - 辉瑞是寻求股息投资者的好选择，股票远期收益率达7.8%，过去十年股息支付提高54% [9]

文章核心观点 - 辉瑞公司在新冠疫苗带来的营收繁荣后经历了艰难的几年 [1] 公司情况 - 辉瑞是全球大规模快速接种疫苗需求的少数受益者之一 [1]

文章核心观点 - 建议参与Out Fox The Street以把握被市场低估的股票投资机会，同时指出辉瑞公司因疫苗担忧股价下跌至22美元，股息收益率飙升至近8% [1] 公司情况 - 辉瑞公司（NYSE: PFE）因疫苗担忧股价下跌至22美元，市场定价反映出对其收入损失的重大担忧，股息收益率飙升至近8% [1]